John R. Asplin
Title | Clinical Associate |
---|
Institution | University of Chicago |
---|
Department | Medicine-Nephrology |
---|
Address | Chicago IL 60637
|
---|
vCard | Download vCard |
---|
|
|
|
Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
Faculty can login to make corrections and additions.
-
Asplin JR. Neglected analytes in the 24-h urine: ammonium and sulfate. Curr Opin Nephrol Hypertens. 2022 03 01; 31(2):168-174. PMID: 34798636.
-
Hood VL, Sternberg KM, de Waal D, Asplin JR, Mulligan C, Callas PW. Association of Urine Findings with Metabolic Syndrome Traits in a Population of Patients with Nephrolithiasis. Kidney360. 2022 02 24; 3(2):317-324. PMID: 35373120.
-
Nazzal L, Francois F, Henderson N, Liu M, Li H, Koh H, Wang C, Gao Z, Perez GP, Asplin JR, Goldfarb DS, Blaser MJ. Effect of antibiotic treatment on Oxalobacter formigenes colonization of the gut microbiome and urinary oxalate excretion. Sci Rep. 2021 08 12; 11(1):16428. PMID: 34385560.
-
Joshi A, Tallman JE, Calvert JK, Brewer T, Miller NL, Yang L, Asplin JR, Hsi RS. Complementary and Alternative Medicine Use in First-time and Recurrent Kidney Stone Formers. Urology. 2021 10; 156:58-64. PMID: 34293376.
-
Prochaska ML, Moe OW, Asplin JR, Coe FL, Worcester EM. Evidence for abnormal linkage between urine oxalate and citrate excretion in human kidney stone formers. Physiol Rep. 2021 07; 9(13):e14943. PMID: 34231328.
-
Tyson CC, Luciano A, Modliszewski JL, Corcoran DL, Bain JR, Muehlbauer M, Ilkayeva O, Pourafshar S, Allen J, Bowman C, Gung J, Asplin JR, Pendergast J, Svetkey LP, Lin PH, Scialla JJ. Effect of Bicarbonate on Net Acid Excretion, Blood Pressure, and Metabolism in Patients With and Without CKD: The Acid Base Compensation in CKD Study. Am J Kidney Dis. 2021 07; 78(1):38-47. PMID: 33810868.
-
Liu M, Devlin JC, Hu J, Volkova A, Battaglia TW, Ho M, Asplin JR, Byrd A, Loke P, Li H, Ruggles KV, Tsirigos A, Blaser MJ, Nazzal L. Microbial genetic and transcriptional contributions to oxalate degradation by the gut microbiota in health and disease. Elife. 2021 03 26; 10. PMID: 33769280.
-
Prochaska M, Asplin J, Chapman A, Worcester E. Sex Differences of Kidney Stone Urine Risk Factors after Roux-en-Y Gastric Bypass. Am J Nephrol. 2021; 52(2):173-176. PMID: 33765680.
-
Krieger NS, Asplin J, Granja I, Chen L, Spataru D, Wu TT, Grynpas M, Bushinsky DA. Chlorthalidone with potassium citrate decreases calcium oxalate stones and increases bone quality in genetic hypercalciuric stone-forming rats. Kidney Int. 2021 05; 99(5):1118-1126. PMID: 33417997.
-
Stern JM, Burk RD, Asplin J, Krieger NS, Suadicani SO, Wang Y, Usyk M, Lee JA, Chen L, Becker J, Chan M, Bushinsky DA. Kidney stone formation and the gut microbiome are altered by antibiotics in genetic hypercalciuric stone-forming rats. Urolithiasis. 2021 Jun; 49(3):185-193. PMID: 33161469.
-
Williams JC, Gambaro G, Rodgers A, Asplin J, Bonny O, Costa-Bauzá A, Ferraro PM, Fogazzi G, Fuster DG, Goldfarb DS, Grases F, Heilberg IP, Kok D, Letavernier E, Lippi G, Marangella M, Nouvenne A, Petrarulo M, Siener R, Tiselius HG, Traxer O, Trinchieri A, Croppi E, Robertson WG. Urine and stone analysis for the investigation of the renal stone former: a consensus conference. Urolithiasis. 2021 Feb; 49(1):1-16. PMID: 33048172.
-
Large T, Williams J, Asplin JR, Krambeck A. Using Low-Calorie Orange Juice as a Dietary Alternative to Alkali Therapy. J Endourol. 2020 10; 34(10):1082-1087. PMID: 32363926.
-
Sui W, Hancock J, Asplin JR, Gould ER, Hsi RS. Nephrolithiasis and Elevated Urinary Ammonium: A Matched Comparative Study. Urology. 2020 10; 144:77-82. PMID: 32544550.
-
Ennis JL, Luo D, Asplin JR, Coe FL. A laboratory-based algorithm to predict future kidney function decline in older adults with reduced estimated glomerular filtration rate?. Clin Nephrol. 2019 Sep; 92(3):113-122. PMID: 31319905.
-
Krieger NS, Asplin JR, Granja I, Ramos FM, Flotteron C, Chen L, Wu TT, Grynpas MD, Bushinsky DA. Chlorthalidone Is Superior to Potassium Citrate in Reducing Calcium Phosphate Stones and Increasing Bone Quality in Hypercalciuric Stone-Forming Rats. J Am Soc Nephrol. 2019 07; 30(7):1163-1173. PMID: 31101664.
-
Wollin DA, Davis LG, Winship BB, Carlos EC, Tom WR, Asplin JR, Kosinski AS, Scales CD, Ferrandino MN, Preminger GM, Lipkin ME. Assessment of conservative dietary management as a method for normalization of 24-h urine pH in stone formers. Urolithiasis. 2020 Apr; 48(2):131-136. PMID: 31062069.
-
Asplin JR, Goldfarb DS. Effect of thiazolidinedione therapy on the risk of uric acid stones. Kidney Int. 2019 05; 95(5):1022-1024. PMID: 31010476.
-
Menezes CJ, Worcester EM, Coe FL, Asplin J, Bergsland KJ, Ko B. Mechanisms for falling urine pH with age in stone formers. Am J Physiol Renal Physiol. 2019 07 01; 317(7):F65-F72. PMID: 31017011.
-
Malieckal DA, Modersitzki F, Mara K, Enders FT, Asplin JR, Goldfarb DS. Effect of increasing doses of cystine-binding thiol drugs on cystine capacity in patients with cystinuria. Urolithiasis. 2019 Dec; 47(6):549-555. PMID: 30980122.
-
Kim D, Rimer JD, Asplin JR. Hydroxycitrate: a potential new therapy for calcium urolithiasis. Urolithiasis. 2019 Aug; 47(4):311-320. PMID: 30915494.
-
Brown L, Luciano A, Pendergast J, Khairallah P, Anderson CAM, Sondheimer J, Hamm LL, Ricardo AC, Rao P, Rahman M, Miller ER, Sha D, Xie D, Feldman HI, Asplin J, Wolf M, Scialla JJ. Predictors of Net Acid Excretion in the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis. 2019 08; 74(2):203-212. PMID: 30910373.
-
Krieger NS, Grynpas M, VandenEynde A, Asplin JR, Frick KK, Kim MH, Ramos FM, Granja I, Bushinsky DA. Low Sodium Diet Decreases Stone Formation in Genetic Hypercalciuric Stone-Forming Rats. Nephron. 2019; 142(2):147-158. PMID: 30726853.
-
Ziemba JB, Gurnani R, Ludwig WW, Gorin MA, Asplin J, Matlaga BR. Individual renal unit urine sampling to identify unilateral metabolic defects?. Clin Nephrol. 2019 Feb; 91(2):87-94. PMID: 30369399.
-
Cheng JW, Wagner H, Asplin JR, Hodgkin G, Schlaifer A, Fargusson M, Fargusson J, Baldwin DD. The Effect of Lemonade and Diet Lemonade Upon Urinary Parameters Affecting Calcium Urinary Stone Formation. J Endourol. 2019 02; 33(2):160-166. PMID: 30585747.
-
Stern JM, Urban-Maldonado M, Usyk M, Granja I, Schoenfeld D, Davies KP, Agalliu I, Asplin J, Burk R, Suadicani SO. Fecal transplant modifies urine chemistry risk factors for urinary stone disease. Physiol Rep. 2019 02; 7(4):e14012. PMID: 30789675.
-
Patel RM, Jiang P, Asplin J, Granja I, Capretz T, Osann K, Okhunov Z, Landman J, Clayman RV. Coconut Water: An Unexpected Source of Urinary Citrate. Biomed Res Int. 2018; 2018:3061742. PMID: 30515390.
-
Bashir M, Meddings J, Alshaikh A, Jung D, Le K, Amin R, Ratakonda S, Sharma S, Granja I, Satti M, Asplin J, Hassan H. Enhanced gastrointestinal passive paracellular permeability contributes to the obesity-associated hyperoxaluria. Am J Physiol Gastrointest Liver Physiol. 2019 01 01; 316(1):G1-G14. PMID: 30307745.
-
Bergsland KJ, Coe FL, Parks JH, Asplin JR, Worcester EM. Evidence for a role of PDZ domain-containing proteins to mediate hypophosphatemia in calcium stone formers. Nephrol Dial Transplant. 2018 05 01; 33(5):759-770. PMID: 29126251.
-
Hinck BD, Miyaoka R, Lingeman JE, Assimos DG, Matlaga BR, Pramanik R, Asplin J, Cohen B, Monga M. Urine kidney injury markers do not increase following gastric bypass: a multi-center cross-sectional study. Can J Urol. 2018 02; 25(1):9199-9204. PMID: 29524975.
-
Amin R, Asplin J, Jung D, Bashir M, Alshaikh A, Ratakonda S, Sharma S, Jeon S, Granja I, Matern D, Hassan H. Reduced active transcellular intestinal oxalate secretion contributes to the pathogenesis of obesity-associated hyperoxaluria. Kidney Int. 2018 05; 93(5):1098-1107. PMID: 29395336.
-
Ellison JS, Hollingsworth JM, Langman CB, Asplin JR, Schwaderer AL, Yan P, Bierlein M, Barraza MA, Defoor WR, Figueroa TE, Jackson EC, Jayanthi VR, Johnson EK, Joseph DB, Shnorhavorian M. Analyte variations in consecutive 24-hour urine collections in children. J Pediatr Urol. 2017 Dec; 13(6):632.e1-632.e7. PMID: 28739373.
-
Hinck BD, Ganesan V, Tarplin S, Asplin J, Granja I, Calle J, Sivalingam S, Monga M. Can a Simplified 12-Hour Nighttime Urine Collection Predict Urinary Stone Risk? Urology. 2017 Oct; 108:40-45. PMID: 28705575.
-
Khairallah P, Isakova T, Asplin J, Hamm L, Dobre M, Rahman M, Sharma K, Leonard M, Miller E, Jaar B, Brecklin C, Yang W, Wang X, Feldman H, Wolf M, Scialla JJ. Acid Load and Phosphorus Homeostasis in CKD. Am J Kidney Dis. 2017 Oct; 70(4):541-550. PMID: 28645705.
-
Ermer T, Kopp C, Asplin JR, Granja I, Perazella MA, Reichel M, Nolin TD, Eckardt KU, Aronson PS, Finkelstein FO, Knauf F. Impact of Regular or Extended Hemodialysis and Hemodialfiltration on Plasma Oxalate Concentrations in Patients With End-Stage Renal Disease. Kidney Int Rep. 2017 Nov; 2(6):1050-1058. PMID: 29270514.
-
Scialla JJ, Asplin J, Wolf M. The Authors Reply. Kidney Int. 2017 06; 91(6):1518-1519. PMID: 28501306.
-
DeFoor W, Jackson E, Schulte M, Alam Z, Asplin J. Calcium-to-Citrate Ratio Distinguishes Solitary and Recurrent Urinary Stone Forming Children. J Urol. 2017 08; 198(2):416-421. PMID: 28365270.
-
Moreland AM, Santa Ana CA, Asplin JR, Kuhn JA, Holmes RP, Cole JA, Odstrcil EA, Van Dinter TG, Martinez JG, Fordtran JS. Steatorrhea and Hyperoxaluria in Severely Obese Patients Before and After Roux-en-Y Gastric Bypass. Gastroenterology. 2017 04; 152(5):1055-1067.e3. PMID: 28089681.
-
Scialla JJ, Asplin J, Dobre M, Chang AR, Lash J, Hsu CY, Kallem RR, Hamm LL, Feldman HI, Chen J, Appel LJ, Anderson CA, Wolf M. Higher net acid excretion is associated with a lower risk of kidney disease progression in patients with diabetes. Kidney Int. 2017 01; 91(1):204-215. PMID: 27914710.
-
Ennis JL, Asplin JR. The role of the 24-h urine collection in the management of nephrolithiasis. Int J Surg. 2016 Dec; 36(Pt D):633-637. PMID: 27840312.
-
Arvans D, Jung YC, Antonopoulos D, Koval J, Granja I, Bashir M, Karrar E, Roy-Chowdhury J, Musch M, Asplin J, Chang E, Hassan H. Oxalobacter formigenes-Derived Bioactive Factors Stimulate Oxalate Transport by Intestinal Epithelial Cells. J Am Soc Nephrol. 2017 Mar; 28(3):876-887. PMID: 27738124.
-
Mulay SR, Eberhard JN, Desai J, Marschner JA, Kumar SV, Weidenbusch M, Grigorescu M, Lech M, Eltrich N, Müller L, Hans W, Hrabe de Angelis M, Vielhauer V, Hoppe B, Asplin J, Burzlaff N, Herrmann M, Evan A, Anders HJ. Hyperoxaluria Requires TNF Receptors to Initiate Crystal Adhesion and Kidney Stone Disease. J Am Soc Nephrol. 2017 Mar; 28(3):761-768. PMID: 27612997.
-
Chung J, Granja I, Taylor MG, Mpourmpakis G, Asplin JR, Rimer JD. Molecular modifiers reveal a mechanism of pathological crystal growth inhibition. Nature. 2016 08 25; 536(7617):446-50. PMID: 27501150.
-
Knauf F, Thomson RB, Heneghan JF, Jiang Z, Adebamiro A, Thomson CL, Barone C, Asplin JR, Egan ME, Alper SL, Aronson PS. Loss of Cystic Fibrosis Transmembrane Regulator Impairs Intestinal Oxalate Secretion. J Am Soc Nephrol. 2017 Jan; 28(1):242-249. PMID: 27313231.
-
Alruwaily AF, Dauw CA, Bierlein MJ, Yan P, Asplin JR, Ghani KR, Wolf JS, Hollingsworth JM. How Much Information is Lost When You Only Collect One 24-Hour Urine Sample during the Initial Metabolic Evaluation? J Urol. 2016 Oct; 196(4):1143-8. PMID: 27140069.
-
Asplin JR. The management of patients with enteric hyperoxaluria. Urolithiasis. 2016 Feb; 44(1):33-43. PMID: 26645872.
-
Ennis J, Gillen D, Rubenstein A, Worcester E, Brecher ME, Asplin J, Coe F. Clinical decision support improves physician guideline adherence for laboratory monitoring of chronic kidney disease: a matched cohort study. BMC Nephrol. 2015 Oct 15; 16:163. PMID: 26471846.
-
Alruwaily AF, Dauw CA, Bierlein MJ, Asplin JR, Ghani KR, Wolf JS, Hollingsworth JM. Geographic Variation in the Quality of Secondary Prevention for Nephrolithiasis. Urology. 2015 Sep; 86(3):454-8. PMID: 26210006.
-
Krieger NS, Asplin JR, Frick KK, Granja I, Culbertson CD, Ng A, Grynpas MD, Bushinsky DA. Effect of Potassium Citrate on Calcium Phosphate Stones in a Model of Hypercalciuria. J Am Soc Nephrol. 2015 Dec; 26(12):3001-8. PMID: 25855777.
-
DeFoor WR, Asplin JR, Kollar L, Jackson E, Jenkins T, Schulte M, Inge T. Prospective evaluation of urinary metabolic indices in severely obese adolescents after weight loss surgery. Surg Obes Relat Dis. 2016 Feb; 12(2):363-7. PMID: 26077697.
-
Moorthi RN, Armstrong CL, Janda K, Ponsler-Sipes K, Asplin JR, Moe SM. The effect of a diet containing 70% protein from plants on mineral metabolism and musculoskeletal health in chronic kidney disease. Am J Nephrol. 2014; 40(6):582-91. PMID: 25613675.
-
Dauw CA, Alruwaily AF, Bierlein MJ, Asplin JR, Ghani KR, Wolf JS, Hollingsworth JM. Provider variation in the quality of metabolic stone management. J Urol. 2015 Mar; 193(3):885-90. PMID: 25286012.
-
Frick KK, Asplin JR, Culbertson CD, Granja I, Krieger NS, Bushinsky DA. Persistence of 1,25D-induced hypercalciuria in alendronate-treated genetic hypercalciuric stone-forming rats fed a low-calcium diet. Am J Physiol Renal Physiol. 2014 May 01; 306(9):F1081-7. PMID: 24573387.
-
Ng AH, Frick KK, Krieger NS, Asplin JR, Cohen-McFarlane M, Culbertson CD, Kyker-Snowman K, Grynpas MD, Bushinsky DA. 1,25(OH)2D3 induces a mineralization defect and loss of bone mineral density in genetic hypercalciuric stone-forming rats. Calcif Tissue Int. 2014 May; 94(5):531-43. PMID: 24481706.
-
Farmanesh S, Ramamoorthy S, Chung J, Asplin JR, Karande P, Rimer JD. Specificity of growth inhibitors and their cooperative effects in calcium oxalate monohydrate crystallization. J Am Chem Soc. 2014 Jan 08; 136(1):367-76. PMID: 24313314.
-
Frick KK, Asplin JR, Krieger NS, Culbertson CD, Asplin DM, Bushinsky DA. 1,25(OH)2D3-enhanced hypercalciuria in genetic hypercalciuric stone-forming rats fed a low-calcium diet. Am J Physiol Renal Physiol. 2013 Oct 15; 305(8):F1132-8. PMID: 23926184.
-
Asplin JR, Penniston K, Goldfarb DS. Monosodium urate stones are rare, and urine pH is not low in cystinuria. Am J Kidney Dis. 2013 Jul; 62(1):179-80. PMID: 23773841.
-
Perry GM, Scheinman SJ, Asplin JR. Effects of Sex on Intra-Individual Variance in Urinary Solutes in Stone-Formers Collected from a Single Clinical Laboratory. PLoS One. 2013; 8(6):e53637. PMID: 23840293.
-
Knauf F, Asplin JR, Granja I, Schmidt IM, Moeckel GW, David RJ, Flavell RA, Aronson PS. NALP3-mediated inflammation is a principal cause of progressive renal failure in oxalate nephropathy. Kidney Int. 2013 Nov; 84(5):895-901. PMID: 23739234.
-
Okonkwo OW, Batwara R, Granja I, Asplin JR, Goldfarb DS. A pilot study of the effect of sodium thiosulfate on urinary lithogenicity and associated metabolic acid load in non-stone formers and stone formers with hypercalciuria. PLoS One. 2013; 8(4):e60380. PMID: 23593205.
-
Becknell B, Carpenter AR, Bolon B, Asplin JR, Ingraham SE, Hains DS, Schwaderer AL, McHugh KM. Struvite urolithiasis and chronic urinary tract infection in a murine model of urinary diversion. Urology. 2013 May; 81(5):943-8. PMID: 23523293.
-
Perry GM, Scheinman SJ, Asplin JR. Weight, age and coefficients of variation in renal solute excretion. Nephron Physiol. 2012; 122(1-2):13-8. PMID: 23595094.
-
Frick KK, Asplin JR, Favus MJ, Culbertson C, Krieger NS, Bushinsky DA. Increased biological response to 1,25(OH)(2)D(3) in genetic hypercalciuric stone-forming rats. Am J Physiol Renal Physiol. 2013 Mar 15; 304(6):F718-26. PMID: 23344574.
-
Asplin DM, Asplin JR. The Interaction of thiol drugs and urine pH in the treatment of cystinuria. J Urol. 2013 Jun; 189(6):2147-51. PMID: 23261477.
-
Block GA, Wheeler DC, Persky MS, Kestenbaum B, Ketteler M, Spiegel DM, Allison MA, Asplin J, Smits G, Hoofnagle AN, Kooienga L, Thadhani R, Mannstadt M, Wolf M, Chertow GM. Effects of phosphate binders in moderate CKD. J Am Soc Nephrol. 2012 Aug; 23(8):1407-15. PMID: 22822075.
-
Leaf DE, Korets R, Taylor EN, Tang J, Asplin JR, Goldfarb DS, Gupta M, Curhan GC. Effect of vitamin D repletion on urinary calcium excretion among kidney stone formers. Clin J Am Soc Nephrol. 2012 May; 7(5):829-34. PMID: 22422535.
-
Bergsland KJ, Coe FL, White MD, Erhard MJ, DeFoor WR, Mahan JD, Schwaderer AL, Asplin JR. Urine risk factors in children with calcium kidney stones and their siblings. Kidney Int. 2012 Jun; 81(11):1140-8. PMID: 22358148.
-
Wu JN, Craig J, Chamie K, Asplin J, Ali MR, Low RK. Urolithiasis risk factors in the bariatric population undergoing gastric bypass surgery. Surg Obes Relat Dis. 2013 Jan-Feb; 9(1):83-7. PMID: 22100051.
-
Sumorok NT, Asplin JR, Eisner BH, Stoller ML, Goldfarb DS. Effect of diet orange soda on urinary lithogenicity. Urol Res. 2012 Jun; 40(3):237-41. PMID: 21858427.
-
Mechlin C, Kalorin C, Asplin J, White M. Splenda® improves tolerance of oral potassium citrate supplementation for prevention of stone formation: results of a randomized double-blind trial. J Endourol. 2011 Sep; 25(9):1541-5. PMID: 21815827.
-
Bushinsky DA, Willett T, Asplin JR, Culbertson C, Che SP, Grynpas M. Chlorthalidone improves vertebral bone quality in genetic hypercalciuric stone-forming rats. J Bone Miner Res. 2011 Aug; 26(8):1904-12. PMID: 21351146.
-
Maalouf NM, Adams Huet B, Pasch A, Lieske JC, Asplin JR, Siener R, Hesse A, Nuoffer JM, Frey FJ, Knight J, Holmes RP, Zerwekh JE, Bonny O. Variability in urinary oxalate measurements between six international laboratories. Nephrol Dial Transplant. 2011 Dec; 26(12):3954-9. PMID: 21454350.
-
Moe SM, Zidehsarai MP, Chambers MA, Jackman LA, Radcliffe JS, Trevino LL, Donahue SE, Asplin JR. Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease. Clin J Am Soc Nephrol. 2011 Feb; 6(2):257-64. PMID: 21183586.
-
Bergsland KJ, Zisman AL, Asplin JR, Worcester EM, Coe FL. Evidence for net renal tubule oxalate secretion in patients with calcium kidney stones. Am J Physiol Renal Physiol. 2011 Feb; 300(2):F311-8. PMID: 21123489.
-
Coe FL, Asplin JR. Medicine. Stopping the stones. Science. 2010 Oct 15; 330(6002):325-6. PMID: 20947749.
-
Odstrcil EA, Martinez JG, Santa Ana CA, Xue B, Schneider RE, Steffer KJ, Porter JL, Asplin J, Kuhn JA, Fordtran JS. The contribution of malabsorption to the reduction in net energy absorption after long-limb Roux-en-Y gastric bypass. Am J Clin Nutr. 2010 Oct; 92(4):704-13. PMID: 20739420.
-
Lambert EH, Asplin JR, Herrell SD, Miller NL. Analysis of 24-hour urine parameters as it relates to age of onset of cystine stone formation. J Endourol. 2010 Jul; 24(7):1179-82. PMID: 20624086.
-
Eisner BH, Asplin JR, Goldfarb DS, Ahmad A, Stoller ML. Citrate, malate and alkali content in commonly consumed diet sodas: implications for nephrolithiasis treatment. J Urol. 2010 Jun; 183(6):2419-23. PMID: 20403610.
-
Semins MJ, Asplin JR, Steele K, Assimos DG, Lingeman JE, Donahue S, Magnuson T, Schweitzer M, Matlaga BR. The effect of restrictive bariatric surgery on urinary stone risk factors. Urology. 2010 Oct; 76(4):826-9. PMID: 20381135.
-
DeFoor WR, Jackson E, Minevich E, Caillat A, Reddy P, Sheldon C, Asplin J. The risk of recurrent urolithiasis in children is dependent on urinary calcium and citrate. Urology. 2010 Jul; 76(1):242-5. PMID: 20110113.
-
Block GA, Persky MS, Ketteler M, Kestenbaum B, Thadhani R, Kooienga L, Spiegel D, Asplin J, Ehrlich J, Dennis V, Nissenson A, Chertow GM, Wheeler DC. A randomized double-blind pilot study of serum phosphorus normalization in chronic kidney disease: a new paradigm for clinical outcomes studies in nephrology. Hemodial Int. 2009 Jul; 13(3):360-2. PMID: 19601992.
-
Asplin JR, Donahue SE, Lindeman C, Michalenka A, Strutz KL, Bushinsky DA. Thiosulfate reduces calcium phosphate nephrolithiasis. J Am Soc Nephrol. 2009 Jun; 20(6):1246-53. PMID: 19369406.
-
Patel V, Nicar M, Emmett M, Asplin J, Maguire JA, Santa Ana CA, Fordtran JS. Intestinal and renal effects of low-volume phosphate and sulfate cathartic solutions designed for cleansing the colon: pathophysiological studies in five normal subjects. Am J Gastroenterol. 2009 Apr; 104(4):953-65. PMID: 19240703.
-
Asplin JR. Obesity and urolithiasis. Adv Chronic Kidney Dis. 2009 Jan; 16(1):11-20. PMID: 19095201.
-
Goodman JW, Asplin JR, Goldfarb DS. Effect of two sports drinks on urinary lithogenicity. Urol Res. 2009 Feb; 37(1):41-6. PMID: 19066876.
-
Patel BN, Passman CM, Fernandez A, Asplin JR, Coe FL, Kim SC, Lingeman JE, Assimos DG. Prevalence of hyperoxaluria after bariatric surgery. J Urol. 2009 Jan; 181(1):161-6. PMID: 19013593.
-
Pramanik R, Asplin JR, Jackson ME, Williams JC. Protein content of human apatite and brushite kidney stones: significant correlation with morphologic measures. Urol Res. 2008 Oct; 36(5):251-8. PMID: 18779958.
-
DeFoor W, Minevich E, Jackson E, Reddy P, Clark C, Sheldon C, Asplin J. Urinary metabolic evaluations in solitary and recurrent stone forming children. J Urol. 2008 Jun; 179(6):2369-72. PMID: 18433777.
-
Asplin JR. Nephrolithiasis: introduction. Semin Nephrol. 2008 Mar; 28(2):97-8. PMID: 18359390.
-
Asplin JR. Evaluation of the kidney stone patient. Semin Nephrol. 2008 Mar; 28(2):99-110. PMID: 18359391.
-
Bushinsky DA, Michalenka AC, Strutz KL, Donahue S, Asplin JR. Effect of bolus and divided feeding on urine ions and supersaturation in genetic hypercalciuric stone-forming rats. Kidney Int. 2008 Feb; 73(4):423-9. PMID: 18046318.
-
Goldfarb DS, Modersitzki F, Asplin JR. A randomized, controlled trial of lactic acid bacteria for idiopathic hyperoxaluria. Clin J Am Soc Nephrol. 2007 Jul; 2(4):745-9. PMID: 17699491.
-
Asplin JR, Coe FL. Hyperoxaluria in kidney stone formers treated with modern bariatric surgery. J Urol. 2007 Feb; 177(2):565-9. PMID: 17222634.
-
DeFoor W, Asplin J, Jackson E, Jackson C, Reddy P, Sheldon C, Erhard M, Minevich E. Urinary metabolic evaluations in normal and stone forming children. J Urol. 2006 Oct; 176(4 Pt 2):1793-6. PMID: 16945651.
-
Asplin JR, Donahue S, Kinder J, Coe FL. Urine calcium excretion predicts bone loss in idiopathic hypercalciuria. Kidney Int. 2006 Oct; 70(8):1463-7. PMID: 16941029.
-
Bushinsky DA, Laplante K, Asplin JR. Effect of cinacalcet on urine calcium excretion and supersaturation in genetic hypercalciuric stone-forming rats. Kidney Int. 2006 May; 69(9):1586-92. PMID: 16557225.
-
Jiang Z, Asplin JR, Evan AP, Rajendran VM, Velazquez H, Nottoli TP, Binder HJ, Aronson PS. Calcium oxalate urolithiasis in mice lacking anion transporter Slc26a6. Nat Genet. 2006 Apr; 38(4):474-8. PMID: 16532010.
-
Goldfarb DS, Coe FL, Asplin JR. Urinary cystine excretion and capacity in patients with cystinuria. Kidney Int. 2006 Mar; 69(6):1041-7. PMID: 16501494.
-
Wolf J, Asplin JR, Goldfarb DS. Chitosan does not reduce post-prandial urinary oxalate excretion. Urol Res. 2006 Aug; 34(4):227-30. PMID: 16506035.
-
Defoor W, Asplin J, Jackson E, Jackson C, Reddy P, Sheldon C, Minevich E. Results of a prospective trial to compare normal urine supersaturation in children and adults. J Urol. 2005 Oct; 174(4 Pt 2):1708-10. PMID: 16148687.
-
Dolin DJ, Asplin JR, Flagel L, Grasso M, Goldfarb DS. Effect of cystine-binding thiol drugs on urinary cystine capacity in patients with cystinuria. J Endourol. 2005 Apr; 19(3):429-32. PMID: 15865542.
-
Bushinsky DA, Asplin JR. Thiazides reduce brushite, but not calcium oxalate, supersaturation, and stone formation in genetic hypercalciuric stone-forming rats. J Am Soc Nephrol. 2005 Feb; 16(2):417-24. PMID: 15647340.
-
Pramanik R, Asplin JR, Lindeman C, Favus MJ, Bai S, Coe FL. Lipopolysaccharide negatively modulates vitamin D action by down-regulating expression of vitamin D-induced VDR in human monocytic THP-1 cells. Cell Immunol. 2004 Nov-Dec; 232(1-2):137-43. PMID: 15876428.
-
Asplin JR, Bauer KA, Kinder J, Müller G, Coe BJ, Parks JH, Coe FL. Bone mineral density and urine calcium excretion among subjects with and without nephrolithiasis. Kidney Int. 2003 Feb; 63(2):662-9. PMID: 12631132.
-
Asplin JR. Hyperoxaluric calcium nephrolithiasis. Endocrinol Metab Clin North Am. 2002 Dec; 31(4):927-49. PMID: 12474639.
-
Raja KA, Schurman S, D'mello RG, Blowey D, Goodyer P, Van Why S, Ploutz-Snyder RJ, Asplin J, Scheinman SJ. Responsiveness of hypercalciuria to thiazide in Dent's disease. J Am Soc Nephrol. 2002 Dec; 13(12):2938-44. PMID: 12444212.
-
Bergsland KJ, Kinder JM, Asplin JR, Coe BJ, Coe FL. Influence of gender and age on calcium oxalate crystal growth inhibition by urine from relatives of stone forming patients. J Urol. 2002 Jun; 167(6):2372-6. PMID: 11992040.
-
Kinder JM, Clark CD, Coe BJ, Asplin JR, Parks JH, Coe FL. Urinary stone risk factors in the siblings of patients with calcium renal stones. J Urol. 2002 May; 167(5):1965-7. PMID: 11956418.
-
Asplin JR, Parks JH, Nakagawa Y, Coe FL. Reduced crystallization inhibition by urine from women with nephrolithiasis. Kidney Int. 2002 May; 61(5):1821-9. PMID: 11967033.
-
Parks JH, Goldfisher E, Asplin JR, Coe FL. A single 24-hour urine collection is inadequate for the medical evaluation of nephrolithiasis. J Urol. 2002 Apr; 167(4):1607-12. PMID: 11912373.
-
Bushinsky DA, Asplin JR, Grynpas MD, Evan AP, Parker WR, Alexander KM, Coe FL. Calcium oxalate stone formation in genetic hypercalciuric stone-forming rats. Kidney Int. 2002 Mar; 61(3):975-87. PMID: 11849452.
-
Parks JH, Asplin JR, Coe FL. Patient adherence to long-term medical treatment of kidney stones. J Urol. 2001 Dec; 166(6):2057-60. PMID: 11696706.
-
Coe FL, Wise H, Parks JH, Asplin JR. Proportional reduction of urine supersaturation during nephrolithiasis treatment. J Urol. 2001 Oct; 166(4):1247-51. PMID: 11547051.
-
Coe FL, Wise H, Parks JH, Fleury PJ, Asplin JR. Differences in urine volume and supersaturation in 2 physician networks. J Urol. 2001 Aug; 166(2):423-8. PMID: 11458041.
-
Coe FL, Clark C, Parks JH, Asplin JR. Solid phase assay of urine cystine supersaturation in the presence of cystine binding drugs. J Urol. 2001 Aug; 166(2):688-93. PMID: 11458118.
-
Hoyer JR, Asplin JR, Otvos L. Phosphorylated osteopontin peptides suppress crystallization by inhibiting the growth of calcium oxalate crystals. Kidney Int. 2001 Jul; 60(1):77-82. PMID: 11422738.
-
Goldfarb DS, Asplin JR. Effect of grapefruit juice on urinary lithogenicity. J Urol. 2001 Jul; 166(1):263-7. PMID: 11435883.
-
Bushinsky DA, Grynpas MD, Asplin JR. Effect of acidosis on urine supersaturation and stone formation in genetic hypercalciuric stone-forming rats. Kidney Int. 2001 Apr; 59(4):1415-23. PMID: 11260403.
-
Nakagawa Y, Asplin JR, Goldfarb DS, Parks JH, Coe FL. Clinical use of cystine supersaturation measurements. J Urol. 2000 Nov; 164(5):1481-5. PMID: 11025687.
-
Lam GS, Asplin JR, Halperin ML. Does a high concentration of calcium in the urine cause an important renal concentrating defect in human subjects? Clin Sci (Lond). 2000 Mar; 98(3):313-9. PMID: 10677390.
-
Bushinsky DA, Parker WR, Asplin JR. Calcium phosphate supersaturation regulates stone formation in genetic hypercalciuric stone-forming rats. Kidney Int. 2000 Feb; 57(2):550-60. PMID: 10652032.
-
Scheinman SJ, Cox JP, Lloyd SE, Pearce SH, Salenger PV, Hoopes RR, Bushinsky DA, Wrong O, Asplin JR, Langman CB, Norden AG, Thakker RV. Isolated hypercalciuria with mutation in CLCN5: relevance to idiopathic hypercalciuria. Kidney Int. 2000 Jan; 57(1):232-9. PMID: 10620204.
-
Asplin JR, Parks JH, Chen MS, Lieske JC, Toback FG, Pillay SN, Nakagawa Y, Coe FL. Reduced crystallization inhibition by urine from men with nephrolithiasis. Kidney Int. 1999 Oct; 56(4):1505-16. PMID: 10504502.
-
Lingeman J, Kahnoski R, Mardis H, Goldfarb DS, Grasso M, Lacy S, Scheinman SJ, Asplin JR, Parks JH, Coe FL. Divergence between stone composition and urine supersaturation: clinical and laboratory implications. J Urol. 1999 Apr; 161(4):1077-81. PMID: 10081841.
-
Bushinsky DA, Neumann KJ, Asplin J, Krieger NS. Alendronate decreases urine calcium and supersaturation in genetic hypercalciuric rats. Kidney Int. 1999 Jan; 55(1):234-43. PMID: 9893132.
-
Lingeman J, Mardis H, Kahnoski R, Goldfarb DS, Lacy S, Grasso M, Scheinman SJ, Parks JH, Asplin JR, Coe FL. Medical reduction of stone risk in a network of treatment centers compared to a research clinic. J Urol. 1998 Nov; 160(5):1629-34. PMID: 9783920.
-
Pillay SN, Asplin JR, Coe FL. Evidence that calgranulin is produced by kidney cells and is an inhibitor of calcium oxalate crystallization. Am J Physiol. 1998 08; 275(2):F255-61. PMID: 9691016.
-
Asplin J, Parks J, Lingeman J, Kahnoski R, Mardis H, Lacey S, Goldfarb D, Grasso M, Coe F. Supersaturation and stone composition in a network of dispersed treatment sites. J Urol. 1998 Jun; 159(6):1821-5. PMID: 9598467.
-
Asplin JR, Lingeman J, Kahnoski R, Mardis H, Parks JH, Coe FL. Metabolic urinary correlates of calcium oxalate dihydrate in renal stones. J Urol. 1998 Mar; 159(3):664-8. PMID: 9474121.
-
Asplin JR, Arsenault D, Parks JH, Coe FL, Hoyer JR. Contribution of human uropontin to inhibition of calcium oxalate crystallization. Kidney Int. 1998 Jan; 53(1):194-9. PMID: 9453018.
-
Asplin JR, Parks JH, Coe FL. Dependence of upper limit of metastability on supersaturation in nephrolithiasis. Kidney Int. 1997 Dec; 52(6):1602-8. PMID: 9407506.
-
Asplin JR, Bushinsky DA, Singharetnam W, Riordon D, Parks JH, Coe FL. Relationship between supersaturation and crystal inhibition in hypercalciuric rats. Kidney Int. 1997 Mar; 51(3):640-5. PMID: 9067894.
-
Asplin JR. Uric acid stones. Semin Nephrol. 1996 Sep; 16(5):412-24. PMID: 8890397.
-
Porile JL, Asplin JR, Parks JH, Nakagawa Y, Coe FL. Normal calcium oxalate crystal growth inhibition in severe calcium oxalate nephrolithiasis. J Am Soc Nephrol. 1996 Apr; 7(4):602-7. PMID: 8724894.
-
Asplin JR, Mandel NS, Coe FL. Evidence of calcium phosphate supersaturation in the loop of Henle. Am J Physiol. 1996 Apr; 270(4 Pt 2):F604-13. PMID: 8967338.
-
Coe FL, Nakagawa Y, Asplin J, Parks JH. Role of nephrocalcin in inhibition of calcium oxalate crystallization and nephrolithiasis. Miner Electrolyte Metab. 1994; 20(6):378-84. PMID: 7783700.
-
Coe FL, Parks JH, Asplin JR. The pathogenesis and treatment of kidney stones. N Engl J Med. 1992 Oct 15; 327(16):1141-52. PMID: 1528210.
-
Asplin J, DeGanello S, Nakagawa YN, Coe FL. Evidence that nephrocalcin and urine inhibit nucleation of calcium oxalate monohydrate crystals. Am J Physiol. 1991 Nov; 261(5 Pt 2):F824-30. PMID: 1951713.
This graph shows the total number of publications by year, by first, middle/unknown, or last author.
To see the data from this visualization as text, click here.
Year | Publications |
---|
1991 | 1 | 1992 | 1 | 1994 | 1 | 1996 | 3 | 1997 | 2 | 1998 | 5 | 1999 | 3 | 2000 | 4 | 2001 | 7 | 2002 | 7 | 2003 | 1 | 2004 | 1 | 2005 | 3 | 2006 | 6 | 2007 | 3 | 2008 | 6 | 2009 | 4 | 2010 | 8 | 2011 | 5 | 2012 | 4 | 2013 | 9 | 2014 | 3 | 2015 | 6 | 2016 | 7 | 2017 | 7 | 2018 | 5 | 2019 | 12 | 2020 | 4 | 2021 | 8 | 2022 | 1 |
To return to the timeline, click here.
|
Asplin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|